June 27, 2017 / 11:23 AM / a year ago

BRIEF-ADMA Biologics provides corporate timeline and activities update

June 27 (Reuters) - Adma Biologics Inc

* ADMA Biologics provides corporate timeline and activities update to stockholders

* Anticipate that co will be in a position to refile biologics license application for RI-002 in middle of 2018

* Is exploring various financing options which would be expected to allow co to extend current cash runway from Q1 2018 to H2 of 2018

* Previously issued warning letter for manufacturing facility cited filter clogging during manufacturing process for Bivigam

* Have identified number of possible sources for filter clogging and working to prioritize and resolve these various possibilities

* Anticipate manufacturing facility will be ready to begin manufacturing certain products for in approximately 8 weeks

* “we are focused on relaunching Bivigam” Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below